Though RNA signatures have been studied in PDAC, a clinically meaningful tool has not yet been developed. The purpose of the COMPASS trial was to use molecular characterization of patients with PDAC prior to treatment to identify predictive and prognostic biomarkers. Read more . . .
The Moffitt gene sets of locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) identified a poor prognostic group, according to a study presented at the 2018 AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachusetts.